RxDoctor Payments Data

Mildred Shrubb

Psychiatric/Mental Health · Cerritos, CANPI 1922317544

Payments from drug & device makers

$4,967in general payments, 2019–2025

Across 137 payments — averaging $36.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$263
  • Sunovion Pharmaceuticals Inc.$251
  • E.r. Squibb & Sons, L.L.C.$137
  • Teva Pharmaceuticals USA, Inc.$124
  • plus $101 from 1 others

What the payments were for

  • Food & beverage$4,86798%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,967 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$10,178
Medicare patients
53
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate128$375,611
Invega TrinzaPaliperidone Palmitate16$121,648
GeodonZiprasidone Hcl43$75,731
Abilify MaintenaAripiprazole15$41,842
LybalviOlanzapine/Samidorphan Malate11$16,889
Lurasidone Hcl28$10,531
Clozapine59$5,233
Aripiprazole100$4,159
Haloperidol Decanoate111$4,014
Olanzapine OdtOlanzapine17$2,347
Clozapine OdtClozapine11$2,230
Ziprasidone Hcl41$1,483
Quetiapine Fumarate90$1,473
Haloperidol41$1,452
Benztropine Mesylate131$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$2,131$497,259144 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$101$41,84215 claims
Alkermes, Inc.Lybalvi$1,958$16,88911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Cerritos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →